A phase Ib dose finding study assessing safety and activity of [177Lu]Lu-NeoB in combination with ribociclib and fulvestrant in participants with ER+, HER2- and GRPR+ advanced breast cancer who have relapsed early from (neo)adjuvant endocrine therapy or who have progressed on endocrine therapy in combination with a CDK4/6 inhibitor.

Status

Recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-502465-18-00

Acronym

CAAA603B12101

Enrollment

Registered

2023-08-21

Start date

2024-02-15

Completion date

Unknown

Last updated

2025-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced or metastatic breast cancer

None listed

Sex/Gender

All

Age

18 Years to No maximum

France, Germany, Poland, Portugal, Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026